Trial Profile
A Randomized Double-blind (Sponsor Unblind) Placebo Controlled Study in Healthy Subjects to Evaluate: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Repeat Doses of GSK2881078, the Selective Androgen Receptor Modulator With an Open Label Dosing Arm to Evaluate the Effect of CYP3A4 Inhibition on Pharmacokinetics of GSK2881078
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 2881078 (Primary) ; Itraconazole
- Indications Cachexia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 02 Jul 2018 Results published in the Journal of Clinical Endocrinology and Metabolism
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 11 Jan 2017 Status changed from recruiting to completed.